Leaflet PULMOZYME 2500U / 2.5ml solution for inhalation by nebuliser
Product code: W61214001 Quantity: 6
Indicated for: cystic fibrosis
Route of administration: inhalation
Substance: dornase alfa (enzyme)
ATC: R05CB13 (Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics)
Dornaza alfa is a medication used for the treatment of cystic fibrosis. It is a recombinant enzyme that breaks down DNA in the thick mucus accumulated in the lungs, facilitating its clearance and improving respiratory function.
The medication is administered via inhalation, usually once daily, using a nebulizer. It is effective in reducing the frequency of respiratory infections and alleviating respiratory symptoms.
Side effects may include sore throat, hoarseness, skin rash, and, in rare cases, severe allergic reactions. Regular monitoring is essential to assess treatment effectiveness.
Consult your doctor to discuss the benefits and risks of treatment with Dornaza alfa. Follow the usage instructions to ensure therapy effectiveness.
General data about PULMOZYME 2500U / 2.5ml
- Substance: dornase alfa
- Date of latest medicines list: 01-06-2026
- Product code: W61214001
- Concentration: 2500U / 2.5ml
- Pharmaceutical form: solution for inhalation by nebuliser
- Packing volume: 2,5 ml
- Product type: Original
- Price: 549.37 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for dornase alfa
Concentrations available for dornase alfa
- 1mg/ml
- 2500U/2.5ml